Skip to main content

Table 3 Management of women by histopathologic diagnosis

From: Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage

Histopathologic diagnosis Management Row total
No treatment indicated (row%) (column%) Immediate management based on colposcopic impression (row%) (column%) Delayed excisional treatment on a recall visit (row%) (column%)
With ablation With LLETZ Completed Pendinga
<CIN2 1158 (88.7%) (100.0%) 90 (6.9%) (78.9%) 54 (4.1%) (69.2%) 3c (0.2%) (12.0%) 0 1305 (100%)
CIN2 Diagnosed on biopsy/LLETZ 0 10 (40.0%) (8.8%) 11 (44.0%) (14.1%) 2 (8.0%) (8.0%) 2 (8.0%) (16.7%) 25 (100%)
Diagnosed on ECC 0 0 0 8 (66.7%) (32.0%) 4 (33.3%) (33.3%) 12 (100%)
CIN3 Diagnosed on biopsy/LLETZ 0 13 (38.2%) (11.4%) 12 (35.3%) (15.4%) 5 (14.7%) (20.0%) 4 (11.8%) (33.3%) 34 (100%)
Diagnosed on ECCb 0 1 (16.7%) (0.9%) 0 3 (50.0%) (12.0%) 2 (33.3%) (16.7%) 6 (100%)
Cancer Diagnosed on biopsy/LLETZ 0 0 1d (20.0%) (1.3%) 4 (80.0%) (16.0%) 0 5 (100%)
Column total 1158 (100%) 114 (100%) 78 (100%) 25 (100%) 12 (100%) Grand total = 1387
  1. aRecall attempts are temporarily paused due to COVID-19 pandemic spread
  2. bIncludes two women with OncoE6 HPV 16 positive, in whom LLETZ was recommended on recall and is still incomplete
  3. cIncludes one case with colposcopic impression of cancer treated with hysterectomy of what eventually turned out to be <CIN2; other two cases were recalled for LLETZ due to reporting error
  4. dInvasive squamous cell carcinoma with CIN3 at margins was diagnosed on on-site LLETZ leading to a recall for a repeat LLETZ with CIN3 diagnosis leading to a 2nd recall for a hysterectomy